ArticleJournal of ovarian research2026
From Yin-deficiency to therapy: molecular mechanisms and drug discovery in high-grade serous ovarian cancer.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Yin-deficiency and Yang-deficiency, key concepts in traditional Chinese medicine, are linked to various health conditions, but their molecular mechanisms are not well understood. High-grade serous ovarian cancer (HGSOC) is a malignancy with high mortality, and the impact of these deficiencies on the disease’s progression and patient outcomes is unknown. This study investigates the impact of these deficiencies on HGSOC by examining the molecular and cellular differences between balance, Yin-deficiency, and Yang-deficiency states. We performed differential gene expression analysis to compare the transcriptomes of these states, conducted Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses, and used LASSO regression to classify subjects. Survival analysis assessed the prognostic significance of Yin-deficiency in HGSOC, and immune cell infiltration was analyzed to understand underlying cellular mechanisms. Drug screening was conducted to identify potential therapies targeting Yin-deficiency-related gene expression changes. We identified 374 differentially expressed genes (DEGs) in Yin-deficiency and 398 DEGs in Yang-deficiency subjects. The DEGs were enriched in pathways related to protein methylation, immune response, and metabolism. Survival analysis revealed that Yin-deficiency is associated with poorer prognosis (HR 1.5, 95% CI 1.05–2.20) in HGSOC. Immune cell analysis revealed distinct profiles in Yin-deficiency patients. The gene Napepld was identified as a candidate biomarker of chemotherapy response. Drug screening identified candidate drug anisomycin that could potentially enhance apoptosis, decrease exosome, and down-regulate Napepld. This study highlights Yin-deficiency as an associated prognostic factor and identifies potential markers and therapies for targeted treatment in HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.